Provenge, CMS, MEDCAC – Prostate Cancer Roundtable press release

Medicare Evidence Development and Coverage Advisory Committee; Centers for Medicare and Medicaid Services; Least Costly Alternative; LCA; Food and Drug Administration; FDA; National Comprehensive Cancer Network; asymptomatic; minimally symptomatic metastatic castrate resistant; hormone refractory; chemotherapy; American Society of Clinical Oncology; Milliman; Herceptin; Avastin; Alimta